HRP20050886B1 - Kruti farmaceutski pripravci koji sadrze agonist s1p receptora i secerni alkohol - Google Patents

Kruti farmaceutski pripravci koji sadrze agonist s1p receptora i secerni alkohol

Info

Publication number
HRP20050886B1
HRP20050886B1 HR20050886A HRP20050886A HRP20050886B1 HR P20050886 B1 HRP20050886 B1 HR P20050886B1 HR 20050886 A HR20050886 A HR 20050886A HR P20050886 A HRP20050886 A HR P20050886A HR P20050886 B1 HRP20050886 B1 HR P20050886B1
Authority
HR
Croatia
Prior art keywords
alkyl
alkoxycarbonyl
branched
straight
carbon chain
Prior art date
Application number
HR20050886A
Other languages
English (en)
Inventor
Oomura Tomoyuki
Pudipeddi Madhusudhan
Edward Royce Alan
Ruegger Colleen
Sasaki Masaki
Tamura Tokuhiro
Original Assignee
Novartis Ag
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corporation filed Critical Novartis Ag
Publication of HRP20050886A2 publication Critical patent/HRP20050886A2/xx
Publication of HRP20050886B1 publication Critical patent/HRP20050886B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kruti farmaceutski pripravak prikladan za oralnu primjenu, naznacen time, da sadrzia) agonist S1P receptora; te b) secerni alkohol, gdje agonist S1P receptora je izabran izmedu- spoja formule Igdje R1 je ravni ili razgranati (C12-22)ugljikov lanac-koji moze u lancu imati vezu ili heteroatom izabrane izmedu dvostruke veze, trostruke veze, O, S, NR6, pri cemu R6 je H, alkil, aralkil, acil ili alkoksikarbonil, te karbonil, i/ili- koji kao supstituent moze imati alkoksi, alkeniloksi, alkiniloksi, aralkiloksi, acil, alkilamino, alkiltio, acilamino, alkoksikarbonil, alkoksikarbonilamino, aciloksi, alkilkarbamoil, nitro, halogen, amino, hidroksimino, hidroksi ili karboksi; iliR1 je- fenilalkil gdje alkil je ravni ili razgranati (C6-20)ugljikov lanac; ili- fenilalkil gdje alkil je ravni ili razgranati (C1-30)ugljikov lanac gdje navedeni fenilalkil je supstituiran s - ravnim ili razgranatim (C6-20)ugljikovim lancem po izboru supstituiranim s halogenom, - ravnim ili razgranatim (C6-20)alkoksi lancem po izboru supstituiranim s halogenom, - ravnim ili razgranatim (C6-20)alkeniloksi, - fenilalkoksi, halofenilalkoksi, fenilalkoksialkil, fenoksialkoksi ili fenoksialkil, - cikloalkilalkil supstituiranim s (C6-20)alkil, - heteroarilalkil supstituiranim s (C6-20)alkil, - heterociklickim C6-20alkil ili- heterociklickim alkil supstituiranim s C2-20alkil, te gdje alkilni dio moze imati - u ugljikovom lancu vezu ili heteroatom izabrane izmedu dvostruke veze, trostruke veze, O, S, sulfinil, sulfonil ili NR6, pri cemu R6 je isti kao gore odreden, te - kao supstituent alkoksi, alkeniloksi, alkiniloksi, aralkiloksi, acil, alkilamino, alkiltio, acilamino, alkoksikarbonil, alkoksikarbonilamino, aciloksi, alkilkarbamoil, nitro, halogen, amino, hidroksi ili karboksi; tesvaki od R2, R3, R4 i R5, neovisno je H, C1-4alkil ili acil; ili njegove farmakoloski prihvatljive soli. Patent sadrzi jos 17 patentnih zahtjeva.
HR20050886A 2003-04-08 2005-10-06 Kruti farmaceutski pripravci koji sadrze agonist s1p receptora i secerni alkohol HRP20050886B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (2)

Publication Number Publication Date
HRP20050886A2 HRP20050886A2 (en) 2006-11-30
HRP20050886B1 true HRP20050886B1 (hr) 2011-01-31

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050886A HRP20050886B1 (hr) 2003-04-08 2005-10-06 Kruti farmaceutski pripravci koji sadrze agonist s1p receptora i secerni alkohol
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20100601AA HRP20100601B1 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol
HR20100600A HRP20100600A2 (hr) 2003-04-08 2010-11-08 Kruti farmaceutski pripravci koji sadrže agonist s1p receptora i šećerni alkohol

Country Status (42)

Country Link
US (11) US20060275357A1 (hr)
EP (5) EP2319502A1 (hr)
JP (3) JP5495467B2 (hr)
KR (3) KR20050121712A (hr)
CN (2) CN1767819B (hr)
AR (3) AR043987A1 (hr)
AT (3) AT501681B1 (hr)
AU (1) AU2004228929B2 (hr)
BE (2) BE1015972A5 (hr)
BR (1) BRPI0409250B8 (hr)
CA (2) CA2707750A1 (hr)
CL (2) CL2004000745A1 (hr)
CY (3) CY1110260T1 (hr)
DE (4) DE102004016947A1 (hr)
DK (2) DK2316431T3 (hr)
EC (1) ECSP056090A (hr)
ES (3) ES2556947T3 (hr)
FR (2) FR2854073B1 (hr)
GB (1) GB2400318B (hr)
GR (1) GR1005052B (hr)
HK (3) HK1071685A1 (hr)
HR (3) HRP20050886B1 (hr)
HU (2) HUE028247T2 (hr)
IL (3) IL170888A (hr)
IS (2) IS2682B (hr)
IT (1) ITMI20040682A1 (hr)
LU (1) LU91867I2 (hr)
MA (1) MA27729A1 (hr)
MX (1) MXPA05010860A (hr)
MY (1) MY141249A (hr)
NO (4) NO329332B1 (hr)
NZ (3) NZ542622A (hr)
PE (5) PE20131352A1 (hr)
PL (2) PL2316431T3 (hr)
PT (1) PT1613288E (hr)
RU (5) RU2358716C2 (hr)
SG (1) SG175449A1 (hr)
SI (2) SI2316431T1 (hr)
TN (1) TNSN05256A1 (hr)
TW (1) TWI332847B (hr)
WO (1) WO2004089341A1 (hr)
ZA (1) ZA200507394B (hr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2829268A1 (en) * 2004-07-30 2015-01-28 Novartis AG Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PT1926483E (pt) * 2005-09-09 2011-03-03 Novartis Ag Tratamento de doenças autoimunes
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
JP2010504364A (ja) * 2006-09-26 2010-02-12 ノバルティス アーゲー Ｓ１ｐ調節剤を含む医薬組成物
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
HUE035990T2 (en) 2007-03-29 2018-05-28 Daiichi Sankyo Co Ltd Pharmaceutical preparation
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
ES2864671T3 (es) * 2007-10-12 2021-10-14 Novartis Ag Composiciones que comprenden moduladores del receptor de esfingosina 1-fosfato (s1p)
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
US11166917B2 (en) * 2008-06-20 2021-11-09 Merck Patent Gmbh Direct injection moldable and rapidly disintegrating tablet matrix
SI2334202T1 (sl) * 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
US20110236428A1 (en) 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CA2743232C (en) * 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd INHIBITOR OF AN ACTIVE FACTOR OF BLOOD COAGULATION
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2010147169A1 (ja) * 2009-06-18 2010-12-23 第一三共株式会社 溶出性の改善された医薬組成物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR101708528B1 (ko) 2010-03-19 2017-02-20 다이이찌 산쿄 가부시키가이샤 디아민 유도체의 결정 및 그 제조 방법
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
EA201291095A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Способ получения пероральной лекарственной формы, содержащей финголимод
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMODE POLYMORPHS AND METHODS THEREOF
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
NO2665471T3 (hr) 2011-01-19 2018-05-26
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
WO2013022059A1 (ja) 2011-08-10 2013-02-14 第一三共株式会社 ジアミン誘導体含有医薬組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US10085955B2 (en) 2013-01-08 2018-10-02 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
US9629834B2 (en) * 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
EP1050301A1 (en) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Medicinal compositions
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
ATE279185T1 (de) 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4153563B2 (ja) * 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
JP4012823B2 (ja) 2001-03-26 2007-11-21 ノバルティス アクチエンゲゼルシャフト ２−アミノ−誘導体
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
JP4217620B2 (ja) 2001-09-27 2009-02-04 杏林製薬株式会社 ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
EP1050301A1 (en) * 1998-01-19 2000-11-08 Yoshitomi Pharmaceutical Industries, Ltd. Medicinal compositions
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Also Published As

Publication number Publication date
EP2319502A1 (en) 2011-05-11
DK2316431T3 (en) 2016-01-11
IS2682B (is) 2010-10-15
AT501681B1 (de) 2012-04-15
NO2011016I2 (no) 2012-08-27
HRP20050886A2 (en) 2006-11-30
BRPI0409250B1 (pt) 2017-07-11
US20200237690A1 (en) 2020-07-30
GB2400318A (en) 2004-10-13
IE20040246A1 (en) 2004-12-15
EP2008650A3 (en) 2011-04-27
PE20090743A1 (es) 2009-07-17
CN101797241B (zh) 2013-03-27
AT504853A2 (de) 2008-08-15
AU2004228929B2 (en) 2008-02-07
RU2012148593A (ru) 2014-05-20
HRP20100600A2 (hr) 2011-03-31
US8324283B2 (en) 2012-12-04
BRPI0409250B8 (pt) 2022-01-18
IL197578A (en) 2015-10-29
GB2400318B (en) 2005-08-10
TWI332847B (en) 2010-11-11
US20060275357A1 (en) 2006-12-07
CY1110260T1 (el) 2014-04-09
US20080311188A1 (en) 2008-12-18
US20090203798A1 (en) 2009-08-13
RU2005134173A (ru) 2006-09-10
ES2228282A1 (es) 2005-04-01
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
JP2004307506A (ja) 2004-11-04
JP2011006461A (ja) 2011-01-13
PT1613288E (pt) 2009-02-25
ATE414508T1 (de) 2008-12-15
NZ586280A (en) 2011-12-22
ZA200507394B (en) 2007-03-28
DE122011100047I1 (de) 2011-12-15
AR078782A2 (es) 2011-11-30
EP1613288B1 (en) 2008-11-19
CY2011013I2 (el) 2014-04-09
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
KR20050121712A (ko) 2005-12-27
GR1005052B (el) 2005-11-30
CA2521325A1 (en) 2004-10-21
PE20131352A1 (es) 2013-11-14
CA2707750A1 (en) 2004-10-21
NO20131287L (no) 2006-01-09
LU91867I9 (hr) 2019-01-03
DK1613288T3 (da) 2009-03-23
PE20130200A1 (es) 2013-03-09
CA2521325C (en) 2010-09-14
PE20150676A1 (es) 2015-05-17
RU2475236C2 (ru) 2013-02-20
IS8885A (is) 2010-02-25
IL242037A0 (en) 2015-11-30
DE102004016947A1 (de) 2004-10-21
NO20055231D0 (no) 2005-11-07
CL2004000745A1 (es) 2005-02-11
MXPA05010860A (es) 2006-05-25
ES2556947T3 (es) 2016-01-21
BE2011C030I2 (hr) 2023-03-07
KR20120101148A (ko) 2012-09-12
MY141249A (en) 2010-03-31
US20140011885A1 (en) 2014-01-09
HK1155647A1 (en) 2012-05-25
EP2316431B1 (en) 2015-09-30
FR2854073A1 (fr) 2004-10-29
EP1613288A1 (en) 2006-01-11
RU2010146697A (ru) 2012-05-27
RU2358716C2 (ru) 2009-06-20
CN1767819B (zh) 2010-07-28
CN101797241A (zh) 2010-08-11
PL1613288T3 (pl) 2009-07-31
NO2011016I1 (no) 2011-09-19
NO335120B1 (no) 2014-09-22
EP2008650A2 (en) 2008-12-31
LU91867I2 (fr) 2011-11-08
CY2011013I1 (el) 2014-04-09
GB0407819D0 (en) 2004-05-12
DE602004017847D1 (de) 2009-01-02
NO20100250L (no) 2006-01-09
JP5495467B2 (ja) 2014-05-21
ES2228282B1 (es) 2006-02-16
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
US20170290787A1 (en) 2017-10-12
NZ542622A (en) 2009-01-31
AT501681A1 (de) 2006-10-15
HRP20100601B1 (hr) 2016-12-02
FR11C0036I1 (fr) 2011-10-14
HK1091114A1 (en) 2007-01-12
RU2010147000A (ru) 2012-08-10
US20110105620A1 (en) 2011-05-05
HRP20100601A2 (hr) 2011-03-31
SI2316431T1 (sl) 2016-04-29
JP2013177404A (ja) 2013-09-09
GR20040100121A (el) 2004-12-17
RU2475237C2 (ru) 2013-02-20
MA27729A1 (fr) 2006-01-02
KR101367574B1 (ko) 2014-02-25
US20130108675A1 (en) 2013-05-02
ECSP056090A (es) 2006-03-01
KR20110005320A (ko) 2011-01-17
AR043987A1 (es) 2005-08-17
US20140255497A1 (en) 2014-09-11
BRPI0409250A (pt) 2006-03-28
SI1613288T1 (sl) 2009-04-30
HUE028247T2 (en) 2016-12-28
US20190175527A1 (en) 2019-06-13
TNSN05256A1 (en) 2007-07-10
CN1767819A (zh) 2006-05-03
NO334116B1 (no) 2013-12-16
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
DE202004021680U1 (de) 2010-04-22
FR11C0036I2 (fr) 2023-12-29
SG175449A1 (en) 2011-11-28
US20220031609A1 (en) 2022-02-03
FR2854073B1 (fr) 2008-03-14
NO329332B1 (no) 2010-09-27
CY1117071T1 (el) 2017-04-05
WO2004089341A1 (en) 2004-10-21
ITMI20040682A1 (it) 2004-07-06
HUS1100016I1 (hu) 2016-08-29
IL170888A (en) 2010-06-16
RU2009105403A (ru) 2010-08-27
EP2769713A1 (en) 2014-08-27
AU2004228929A1 (en) 2004-10-21
AR078781A2 (es) 2011-11-30
PE20050396A1 (es) 2005-07-05
NZ592339A (en) 2012-09-28
TW200503784A (en) 2005-02-01
JP5543298B2 (ja) 2014-07-09
IS8114A (is) 2005-11-01

Similar Documents

Publication Publication Date Title
HRP20050886B1 (hr) Kruti farmaceutski pripravci koji sadrze agonist s1p receptora i secerni alkohol
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BRPI0407616A (pt) composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste&#34;
KR970707098A (ko) 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists)
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
ATE517882T1 (de) Chinolinderivate
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
AR045551A1 (es) Compuestos fenil o piridil amida como prostaglandina e2 antagonistas
IS8708A (is) Kínasólínafleiður sem æðamyndunarhindranir og milliefni fyrir þær
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
BRPI0513888A (pt) composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico
MXPA05012278A (es) Composiciones para suministrar peptido yy y combatientes pyy.
AR041272A1 (es) Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene
TW200626158A (en) Naphthaline derivatives
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
SG158925A1 (en) Modulators of chemokine receptor activity, crystalline forms and process
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
TW200503732A (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives and methods of use thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190401

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200330

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210406

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220404

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20230329

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20240406